Subscribe now

Letter: Negligible risk

Published 26 November 1994

From Paul Schofield, University of Cambridge and Ben Mepham, University of Nottingham

In a response to our letter of 10 September, Samuel Epstein (Letters, 29 October) alleges that we are not aware of evidence suggesting a link between IGF-1 and breast cancer. The matter is of interest in relation to suggestions that levels of IGF-1 may be higher than normal in milk from cows injected with the growth hormone, bovine somatotropin.

However, contrary to Epstein’s contention, there is no evidence that IGF-1 can cause neoplastic transformation in any cell type. Evidence does suggest that, in vitro, selected breast carcinoma cell lines are dependent on either exogenous or endogenously produced IGF-1, but they share this property with countless other normal and abnormal cell types. It is true that IGF-1 is permissive for expression of other transforming mutations, but again this is usually a general requirement for cell growth.

There is conflicting evidence as to whether the acquisition of breast epithelial cells of the ability to synthesise IGF-1 is rate limiting in breast tumourigenesis; the only consistent conclusion is that production of paracrine IGF-1 by the surrounding normal stromal tissue of the breast may contribute to the continued growth of tumours. It is important to draw the distinction between circulating and locally produced IGF-1.

If Epstein is correct, an increase in the incidence of breast cancer should be evident in clinical and experimental conditions where circulating levels of IGF-1 are elevated. The generation of transgenic mice carrying an overexpressed IGF-1 gene, provides no evidence for increased breast tumour incidence, despite somatic overgrowth and high levels of circulating IGF-1. Acromegalic humans similarly have greatly elevated bioactive serum IGF-1, yet have no significantly increased incidence of breast cancer.

By emphasising a negligible risk, Epstein diverts attention from potential effects of milk borne IGF-1 in the gut, an important safety issue, which we believe should be addressed as a matter of urgency.

Issue no. 1953 published 26 November 1994

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up
Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop